TFS Capital’s Pacira BioSciences PCRX Stock Holding History

TFS Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-17,575	Closed	-$838K	–	265
2017 Q2	$838K	Buy	+17,575	New	+$815K	0.33%	94
2016 Q3	–	Sell	-39,189	Closed	-$1.32M	–	924
2016 Q2	$1.32M	Buy	+39,189	New	+$1.93M	0.24%	96
2015 Q4	–	Sell	-14,236	Closed	-$585K	–	861
2015 Q3	$585K	Buy	+14,236	New	+$872K	0.06%	475
2014 Q2	–	Sell	-30,208	Closed	-$2.11M	–	1302
2014 Q1	$2.11M	Buy	+30,208	New	+$2.05M	0.14%	212

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

TFS Capital's PCRX Position: Q3 2017 in Review

TFS Capital sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 17,575 shares — an estimated $838K sold.

TFS Capital first reported a position in PCRX in Q1 2014 and held it in 4 quarters. The position peaked at $2.11M in Q1 2014. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

TFS Capital reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
TFS Capital sold 17,575 Pacira BioSciences shares in Q3 2017, an estimated $838K.
TFS Capital first reported a position in Pacira BioSciences in Q1 2014 and held it in 4 quarters.
TFS Capital's Pacira BioSciences position peaked at $2.11M in Q1 2014.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.